Engineering novel antibody molecules

Chemical Immunology

Volumn 65, Issue , 1997, Pages 129-158

  Sensel, Martha G ^a   Josefina Coloma, M ^a   Harvill, Eric T ^a   Shin, Seung Uon ^a   Smith, Richard I F ^a   Morrison, Sherie L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; HYBRID PROTEIN; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G;

ANTIBODY PRODUCTION; ANTIBODY STRUCTURE; ARTICLE; GENETIC ENGINEERING; IMMUNOGENETICS; PRIORITY JOURNAL; PROTEIN TARGETING;

ANIMALS; GENETIC ENGINEERING; HUMANS; IMMUNOGLOBULINS; RECOMBINANT PROTEINS;

EID: 1842416056     PISSN: 10150145     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (80)

1. Ashkenazi A, Capon DJ, Ward RH: Immunoadhesins. Int Rev Immunol 1993;10:219-227.
2. Capon DJ, Chamow SM, Mordenti J, Marsters SA, Gregory T, Mitsuya H, Byrn RA, Lucas C, Wurm FM, Groopman JE, Broder S, Smith DH: Designing CD4 immunoadhesins for AIDS therapy. Nature 1989;337:525-531.
3. Traunecker A, Schneider J, Kiefer H, Karjalainen K: Highly efficient neutralization of HIV with recombinant CD4-immunoglobulin molecules. Nature 1989;339:68-70.
4. Byrn RA, Mordenti J, Lucas C, Smith D, Marsters SA, Johnson JS, Cossum P, Chamow SM, Wurm FM, Gregory T, Groopman JE, Capon DJ: Biological properties of a CD4 immunoadhesin. Nature 1990;344:667-670.
5. Martin S, Casasnovas JM, Staunton DE, Springer TA: Efficient neutralization and disruption of rhinovirus by chimeric ICAM-1/immunoglobulin molecules. J Virol 1993;67:3561-3568.
6. Landolfi NF: A chimeric IL-2/Ig molecule posseses the functional activity of both proteins. J Immunol 1991;146:915-919.
7. Schnee JM, Runge MS, Matsueda GR, Hudson NW, Seidman JG, Haber E, Quertermous T: Construction and expression of a recombinant antibody-targeted plasminogen activator. Proc Natl Acad Sci USA 1987;84:6904-6908.
8. Hoogenboom HR, Volckaert G, Raus JC: Construction and expression of antibody-tumor necrosis factor fusion proteins. Mol Immunol 1991;28:1027-1037.
9. Gillies SD, Young D, Lo KM, Foley SF, Reisfeld RA: Expression of genetically engineered immunoconjugates of lymphotoxin and a chimeric anti-ganglioside GD2 antibody. Hybridoma 1991;10: 347-356.
10. Duffy KR, Pardridge WM: Blood-brain barrier transcytosis of insulin in developing rabbits. Brain Res 1987;420:32-38.
11. Fishman JB, Rubin JB, Handrahan JV, Connor JR, Fine RE: Receptor-mediated transcytosis of transferrin across the blood-brain barrier. J Neurosci Res 1987;18:299-304.
12. Rosenfeld RG, Pham H, Keller BT, Borchardt RT, Pardridge WM: Demonstration and structural comparison of receptors for insulin-like growth factor-I and -II (IGF-I and -II) in brain and blood-brain barrier. Biochem Biophys Res Commun 1987;149:159-166.
13. Duffy KR, Pardridge WM, Rosenfeld RG: Human blood-brain barrier insulin-like growth factor receptor. Metabolism 1988;37:136-140.
14. Bullard DE, Bourdon M, Bigner DD: Comparison of various methods for delivering radiolabeled monoclonal antibody to normal rat brain. J Neurosurg 1984;61:901-911.
15. Friden PM, Walus LR, Musso GF, Taylor MA, Malfroy B, Starzyk RM: Anti-transferrin receptor antibody and antibody-drug conjugates cross the blood-brain barrier. Proc Natl Acad Sci USA 1991;88:4771-4775.
16. Friden PM, Walus LR, Watson P, Doctrow SR, Kozarich JW, Backman C, Bergman H, Hoffer B, Bloom F, Granholm AC: Blood-brain barrier penetration and in vivo activity of an NGF conjugate. Science 1993;259:373-377.
17. Kordower JH, Charles V, Bayer R, Bartus RT, Putney S, Walus LR, Friden PM: Intravenous administration of a transferrin receptor antibody-nerve growth factor conjugate prevents the degeneration of cholinergic striatal neurons in a model of Huntington disease. Proc Natl Acad Sci USA 1994;91:9077-9080.
18. Shin SU, Morrison SL: Expression and characterization of an antibody specificity joined to insulin-like growth factor 1: Potential applications for cellular targeting. Proc Natl Acad Sci USA 1990; 87:5322-5326.
19. Shin SU, Friden P, Moran M, Morrison SL: Functional properties of antibody insulin-like growth factor fusion proteins. J Biol Chem 1994;269:4979-4985.
20. Shin SU, Friden P, Moran M, Olson T, Kang YS, Pardridge WM, Morrison SL: Transferrin-antibody fusion proteins are effective in brain targeting. Proc Natl Acad Sci USA 1995;92:2820-2824.
21. Tan LK, Shopes RJ, Oi VT, Morrison SL: Influence of the hinge region on complement activation, C1q binding, and segmental flexibility in chimeric human immunoglobulins (published erratum appears in Proc Natl Acad Sci USA 1991;88:5066). Proc Natl Acad Sci USA 1990;87:162-166.
22. Duncan AR, Winter G: The binding site for C1q on IgG. Nature 1988;332:738-740.
23. H2 domain. J Exp Med 1991; 173:1025-1028.
24. Tao MH, Smith RI, Morrison SL: Structural features of human immunoglobulin G that determine isotype-specific differences in complement activation. J Exp Med 1993;178:661-667.
25. Duncan AR, Woof JM, Partridge LJ, Buton DR, Winter G: Localization of the binding site for the human high-affinity Fc receptor on IgG. Nature 1988;332:563-564.
26. H2 domain and is modulated by the hinge region. J Exp Med 1991;173:1483-1491.
27. Chappel MS, Isenman DE, Everett M, Xu YY, Dorrington KJ, Klein MH: Identification of the Fc gamma receptor class I binding site in human IgG through the use of recombinant IgG1/IgG2 hybrid and point-mutated antibodies. Proc Natl Acad Sci USA 1991;88:9036-9040.
28. Lotze MT, Grimm EA, Mazumder A, Strausser JL, Rosenberg SA: Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor. Cancer Res 1981;41: 4420-4425.
29. Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA: Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med 1982;155:1823-1841.
30. Yron I, Wood TA Jr, Spiess PJ, Rosenberg SA: In vitro growth of murine T cells. V. The isolation and growth of lymphoid cells infiltrating syngeneic solid tumors. J Immunol 1980;125:238-245.
31. Hank JA, Surfus J, Gan J, Chew TL, Hong R, Tans K, Reisfeld R, Seeger RC, Reynolds CP, Bauer M, Wiersma S, Hammond D, Sondel P: Treatment of neuroblastoma patients with antiganglioside GD2 antibody plus interleukin-2 induces antibody-dependent cellular cytotoxicity against neuroblastoma detected in vitro. J Immunother 1994;15:29-37.
32. Ponce P, Cruz J, Travassos J, Moreira P, Oliveira J, Melo-Gomes E, Gouveia J: Renal toxicity mediated by continuous infusion of recombinant interleukin-2. Nephron 1993;64:114-118.
33. Siegel JP, Puri RK: Interleukin-2 toxicity. J Clin Oncol 1991;9:694-704.
34. Vial T, Descotes J: Clinical toxicity of interleukin-2. Drug Safety 1992;7:417-433.
35. Donohue JH, Rosenberg SA: The fate of interleukin-2 after in vivo administration. J Immunol 1983;130:2203-2208.
36. Rosenberg SA, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, Seipp CA, Einhorn JH, White DE: Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2 (see comments). JAMA 1994;271:907-913.
37. Riethmuller G, Schneider GE, Johnson JP: Monoclonal antibodies in cancer therapy. Curr Opin Immunol 1993;5:732-739.
38. LeBerthon B, Khwali LA, Alauddin M, Miller GK, Charak BS, Mazumder A, Epstein AL: Enhanced tumor uptake of macromolecules induced by a novel vasoactive interleukin 2 immunoconjugate. Cancer Res 1991;51:2694-2698.
39. Berinstein N, Levy R: Treatment of a murine B cell lymphoma with monoclonal antibodies and IL2. J Immunol 1987;139:971-976.
40. Harvill ET, Morrison SL: An IgG3-IL2 fusion protein activates complement, binds FcγRI, generates LAK activity and shows enhanced binding to the high affinity IL-2R. Immunotechnology 1995;1: 95-105.
41. Harvill ET, Morrison SL: An IgG3-IL-2 fusion protein has higher affinity than hrIL-2 for the IL-2R alpha subunit: Real time measurement of ligand binding. Mol Immunol, in press.
42. Minami Y, Kono T, Miyazaki T, Taniguchi T: The IL-2 receptor complex: Its structure, function, and target genes. Annu Rev Immunol 1993;11:245-268.
43. Sabzevari H, Gillies SD, Mueller BM, Pancook JD, Reisfeld RA: A recombinant antibody-interleukin 2 fusion protein suppresses growth of hepatic human neuroblastoma metastases in severe combined immunodeficiency mice. Proc Natl Acad Sci USA 1994;91:9626-9630.
44. Hank JA, Robinson RR, Surfus J, Mueller BM, Reisfled RA, Cheung NK, Sondel PM: Augmentation of antibody dependent cell mediated cytotoxicity following in vivo therapy with recombinant interleukin 2. Cancer Res 1990;50:5234-5239.
45. Bergman Y, Haimovich J: Characterization of a carcinogen-induced murine B lymphocyte cell line of C3H/eB origin. Eur J Immunol 1977;7:413-417.
46. Maloney DG, Kaminski MS, Burowski D, Haimovich J, Levy R: Monoclonal anti-idiotype antibodies against the murine B cell lymphoma 38C13: Characterization and use as probes for the biology of the tumor in vivo and in vitro. Hybridoma 1985;4:191-209.
47. Kaminski MS, Kitamura K, Maloney DG, Campbell MJ, Levy R: Importance of antibody isotype in monoclonal anti-idiotype therapy of a murine B cell lymphoma. A study of hybridoma class switch variants. J Immunol 1986;136:1123-1130.
48. Berinstein N, Starnes CO, Levy R: Specific enhancement of the therapeutic effect of anti-idiotype antibodies on a murine B cell lymphoma by IL-2. J Immunol 1988;140:2839-2845.
49. Chen TT, Tao MH, Levy R: Idiotype-cytokine fusion proteins as cancer vaccines. Relative efficacy of IL-2, IL-4, and granulocyte-macrophage colony-stimulating factor. J Immunol 1994;153:4775-4787.
50. Hazama M, Mayumi-Aono A, Asakawa N, Kuroda S, Hinuma S, Fujisawa Y: Adjuvant-independent enhanced immune responses to recombinant herpes simplex virus type I glycoprotein D by fusion with biologically active interleukin-2. Vaccine 1993;11:629-636.
51. Hazama M, Mayumi AA, Miyazaki T, Hinuma S, Fujisawa Y: Intranasal immunization against herpes simplex virus infection by using a recombinant glycoprotein D fused with immunomodulating proteins, the B subunit of Escherichia coli heat-labile enterotoxin and interleukin-2. Immunology 1993;78:643-649.
52. Hinuma S, Hazama M, Mayumi A, Fujisawa Y: A novel strategy for converting recombinant viral protein into high immunogenic antigen. FEBS Lett 1991;288:138-142.
53. Nakao M, Hazama M, Mayumi AA, Hinuma S, Fujisawa Y: Immunotherapy of acute and recurrent herpes simplex virus type 2 infection with an adjuvant-free form of recombinant glycoprotein D-interleukin-2 fusion protein. J Infect Dis 1994;169:787-791.
54. Davis AC, Roux KH, Shulman MJ: On the structure of polymeric IgM. Eur J Immunol 1988;18: 1001-1008.
55. Shenoy AM, Brahmi Z: Human IgG1 and mouse IgG3 but not monomeric IgM or IgE facilitate antibody-dependent cell-mediated cytotoxicity by human natural killer cells. Nat Immun Cell Growth Regul 1989;8:338-348.
56. Bruggemann M, Teale C, Clark M, Bindon C, Waldmann H: A matched set of rat/mouse chimeric antibodies. Identification and biological properties of rat H chain constant regions mu, gamma 1, gamma 2a, gamma 2b, gamma 2c, epsilon, and alpha. J Immunol 1989;142:3145-3150.
57. Vieira P, Rajewsky K: The half-lives of serum immunoglobulins in adult mice. Eur J Immunol 1988; 18:313-316.
58. Smith RI, Morrison SL: Recombinant polymeric IgG: An approach to engineering more potent antibodies. Biotechnology 1994;12:683-688.
59. Smith RI, Coloma MJ, Morrison SL: Addition of a mu-tailpiece to IgG results in polymeric antibodies with enhanced effector functions including complement-mediated cytolysis by IgG4. J Immunol 1995;154:2226-2236.
60. Kabat EA, Wu TT, Perry HM, Gottesman KS, Foeller C: Sequence of proteins of immunological interest. NIH Publication No 91-3242, 1991.
61. Uzgiris EE, Kornberg RD: Two-dimensional crystallization technique for imaging macromolecules, with applicationn to antigen-antibody-complement complexes. Nature 1983;301:125-129.
62. Burton DR, Woof JM: Human antibody effector function. Adv Immunol 1992;51:1-84.
63. Anderson CL, Abraham GN: Characterization of the Fc receptor for IgG on a human macrophage cell line, U937. J Immunol 1980;125:2735-2741.
64. Lund J, Pound JD, Jones PT, Duncan AR, Bentley T, Goodall M, Levine BA, Jefferis R, Winter G: Multiple binding sites on the CH2 domain of IgG for mouse Fc gamma R11. Mol Immunol 1992;29:53-59.
65. Ravetch JV, Kinet JP: Fc receptors. Annu Rev Immunol 1991;9:457-492.
66. Feinstein A, Richareson NE, Gorick BD, Hughes-Jones NC: Immunoglobulin M conformational change is a signal for complement activation; in Celada, Shumaker and Sercarz (ed): Immunoglobulin M conformational change is a signal for complement activation. Plenum Press, NY, 1983, pp 47-57.
67. Goldstein GW, Betz AL: The blood-brain barrier. Sci Am 1986;255:74-83.
68. Frank HJ, Pardridge WM, Morris WL, Rosenfeld RG, Choi TB: Binding and internalization of insulin and insulin-like growth factors by isolated brain microvessels. Diabetes 1986;35:654-661.
69. Huebers HA, Finch CA: The physiology of transferrin and transferrin receptors. Physiol Rev 1987; 67:520-582.
70. Pardridge WM, Eisenberg J, Yang J: Human blood-brain barrier transferrin receptor. Metabolism 1987;36:892-895.
71. Bayne ML, Applebaum J, Chicchi GG, Hayes NS, Green NG, Cascieri MA: Structural analogs of human insulin-like growth factor I with reduced affinity for serum binding proteins and the type 2 insulin-like growth factor receptor. J Biol Chem 1988;263:6233-6239.
72. Cascieri MA, Saperstein R, Hayes NS, Green BG, Chicchi GG, Applebaum J, Bayne ML: Serum half-life and biological activity of mutants of human insulin-like growth factor I which do not bind to serum binding proteins. Endocrinology 1988;123:373-381.
73. Ballard FJ, Read LC, Francis GL, Bagley CJ, Wallace JC: Binding properties and biological potencies of insulin-like growth factors in L6 myoblasts. Biochem J 1986;233:223-230.
74. Szabo L, Mottershead DG, Ballard FJ, Wallace JC: The bovine insulin-like growth factor (IGF) binding protein purified from conditioned medium requires the N-terminal tripeptide in IGF-1 for binding. Biochem Biophys Res Commun 1988;151:207-214.
75. Walton PE, Baxter RC, Burleigh BD, Etherton TD: Purification of the serum acid-stable insulin-like growth factor binding protein from the pig (Sus scrofa). Comp Biochem Physiol [b] 1989;92: 561-567.
76. Sitia R, Neuberger M, Alberini C, Bet P, Fra A, Valetti C, Williams G, Milstein C: Developmental regulation of IgM secretion: The role of the carboxy-terminal cysteine. Cell 1990;60:781-790.
77. Isenman DE, Dorrington KJ, Painter RH: The structure and function of immunoglobulin domains. II. The importance of interchain disulfide bonds and the possible role of molecular flexibility in the interaction between immunoglobulin G and complement. J Immunol 1975;114:1726-1729.
78. Dangl JL, Wensel TG, Morrison SL, Stryer L, Herzenberg LA, Oi VT: Segmental gelxibility and complement fixation of genetically engineered chimeric human, rabbit and mouse antibodies. EMBO J 1988;7:1989-1994.
79. Bruggemann M, Williams GT, Bindon CI, Clark MR, Walker MR, Jefferis R, Waldmann H, Neuberger MS: Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies. J Exp Med 1987;166:1351-1361.
80. Hughes-Jones NC, Gardner B: Reaction between the isolated globular sub-units of the complement component C1q and IgG-complexes. Mol Immunol 1979;16:697-701.